Lixte Net Receivables from 2010 to 2024

LIXT Stock  USD 2.07  0.44  26.99%   
Lixte Biotechnology Net Receivables yearly trend continues to be comparatively stable with very little volatility. Net Receivables will likely drop to about 12.3 K in 2024. From the period from 2010 to 2024, Lixte Biotechnology Net Receivables quarterly data regression had r-value of (0.79) and coefficient of variation of  108.22. View All Fundamentals
 
Net Receivables  
First Reported
2010-12-31
Previous Quarter
12.9 K
Current Value
12.3 K
Quarterly Volatility
89.6 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 17 K, Other Operating Expenses of 2.7 M or EBITDA of 3.4 K, as well as many indicators such as Price To Sales Ratio of 9.35, Dividend Yield of 0.0011 or PTB Ratio of 1.18. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Lixte Biotechnology Correlation against competitors.

Latest Lixte Biotechnology's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Lixte Biotechnology Holdings over the last few years. It is Lixte Biotechnology's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Lixte Net Receivables Regression Statistics

Arithmetic Mean82,818
Geometric Mean39,048
Coefficient Of Variation108.22
Mean Deviation82,610
Median14,367
Standard Deviation89,622
Sample Variance8B
Range187.7K
R-Value(0.79)
Mean Square Error3.2B
R-Squared0.63
Significance0.0004
Slope(15,895)
Total Sum of Squares112.4B

Lixte Net Receivables History

202412.3 K
202312.9 K
201614.4 K
2011200 K
2010116.5 K

About Lixte Biotechnology Financial Statements

Lixte Biotechnology shareholders use historical fundamental indicators, such as Net Receivables, to determine how well the company is positioned to perform in the future. Although Lixte Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Lixte Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Lixte Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Receivables12.9 K12.3 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.